You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches

59 search results for: mechanism of disease

The Burden <b>of</b> Atopic Dermatitis in Children – Skin Infections and More Severe <b>Disease</b>
expert video

The Burden of Atopic Dermatitis in Children – Skin Infections and More Severe Disease

Dermatology
Dr. Mark Koh talks about skin infections and their impact on disease severity.
View more
AD, PN, and CSU: Distinct, Pruritic <b>Disease</b>s
expert video

AD, PN, and CSU: Distinct, Pruritic Diseases

Dermatology
Dr. Elmariah explains how AD, PN, and CSU are distinct diseases with the common, burdensome symptom of itch.
View more
COPD and Asthma: What's the Difference and Is There a Link?
interactivity

COPD and Asthma: What's the Difference and Is There a Link?

Pulmonology
Explore the characteristics of COPD and asthma, focusing on their shared inflammatory mechanisms and key clinical differences.
View more
Impact <b>of</b> Advanced Systemic Therapies on <b>Disease</b> Control in AD
expert video

Impact of Advanced Systemic Therapies on Disease Control in AD

Dermatology
Dr. Simpson discusses impact of advanced systemic therapies in AD, and the link between inhibition of type 2 inflammation and reduced IgE levels.
View more
Atopic Dermatitis (AD) is a Type 2 Inflammatory <b>Disease</b>
videoanimation

Atopic Dermatitis (AD) is a Type 2 Inflammatory Disease

Dermatology
Discover the pathophysiological mechanisms involved in atopic dermatitis.
View more
Neuroimmune Axis in Atopic Dermatitis
expert video

Neuroimmune Axis in Atopic Dermatitis

Dermatology
A review of the neuroimmune mechanisms and changes to skin barrier that result in itch in AD.
View more
Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​
expert video

Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​

Dermatology
A review of the shared and unique neuroimmune mechanisms in the generation of itch across AD, PN, and CSU.
View more
<b>Disease</b>-Specific Aspects <b>of</b> Itch in AD, PN, and CSU
expert video

Disease-Specific Aspects of Itch in AD, PN, and CSU

Dermatology
Examination of the unique ways type 2 inflammation contributes to itch in AD, PN, and CSU.
View more
ERS 2024 | A Breath <b>of</b> Fresh Air: A Greater Understanding <b>of</b> COPD With Type 2 Inflammation
expert video

ERS 2024 | A Breath of Fresh Air: A Greater Understanding of COPD With Type 2 Inflammation

Pulmonology
Professors Henrik Watz, Mona Bafadhel, and Alberto Papi discuss the pathophysiology of COPD with type 2 inflammation and review current and emerging biologic therapies
View more
Normalizing Skin Barrier by Inhibiting IL-4 & IL-13, or IL-13 Alone
expert video

Normalizing Skin Barrier by Inhibiting IL-4 & IL-13, or IL-13 Alone

Dermatology
Dr. Ramien explores how advanced systemic therapies may modify atopic dermatitis pathomechanisms including skin barrier dysfunction, and neuroimmune dysregulation
View more
The Potential Impact <b>of</b> Early Intervention in Atopic Dermatitis in Children
expert video

The Potential Impact of Early Intervention in Atopic Dermatitis in Children

Dermatology
Dr. Amy Paller shares her opinion of whether treatment is needed when children might outgrow their disease.
View more
ERS 2024 | What Do We Know About IL-33 Genetics?
expert video

ERS 2024 | What Do We Know About IL-33 Genetics?

Pulmonology
Dr. Stephanie Christenson examines the genetic and environmental factors influencing IL-33 expression and activity in COPD, highlighting the complex interplay between genetics, smoking, and disease pathogenesis.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: AlgeriaChange country/region